Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dermira Ends Acne Program After Phase III Failure, Tries To Keep Focus On Hyperhidrosis Drug

Executive Summary

FDA approval for DRM04 in hyperhidrosis is expected at the end of June, but Phase III data for DRM01 in acne was the main event for investors. CEO Tom Wiggans said Dermira will try to understand what went wrong, while staying focused on DRM04 commercialization and lebrikizumab in Phase IIb.

You may also be interested in...

Cassiopea Wins With Winlevi Acne Phase III Data

The Italian-headquartered, Swiss-listed company spun out of Cosmo Pharmaceuticals has moved a step closer to having the first topical anti-androgen drug approved for acne.

No Sweat – Hyperhidrosis Patients Seek Broader Approvals; Botox Access An Issue

US FDA not looking to reduce attendance at third-party patient meetings, which deliver 'bang for the buck.' Excessive sweating is first externally led PFDD meeting for a more common condition.

Dermira Ends UCB Cimzia Psoriasis Pact To Focus On Its Own Pipeline

As it ends its pact with UCB, Dermira says it needs to focus on its own top assets and couldn't simultaneously launch Cimzia in psoriasis.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts